case report aspiration during anesthesia glp-1 receptor agonist 2023 Managing patients taking glucagon-like peptide-1 Peri-Procedural Safety of GLP-1 Receptor

Tirzepatide, marketed as Zepbound for weight management, has shown higher average weight loss than semaglutide in many trial comparisons

Curr Issues Mol Biol (2023) 45(6):454456

Of those who used them exclusively for weight loss, the majority (91.4% [85.697.2%]) reported using medications licensed for this purpose in Great Britain, most commonly Mounjaro (tirzepatide

Emerging research and real-world experience suggest GLP-1 meds help reduce flares, pain, and inflammation in various inflammatory and autoimmune diseases, especially when obesity or insulin resistance is also present. What are the current barriers to getting GLP-1 medications (cost, coverage)

Invited to give a presentation on GLUT2, he quickly gained the attention of people from Novo Nordisk when he briefly mentioned his work on the GLP-1 receptor at the end of his talk which he had not yet published

Landmark clinical trials, such as the STEP programme for semaglutide published in The New England Journal of Medicine, have demonstrated that these medications can lead to average weight loss of 15% or more when combined with lifestyle changes, a level of efficacy previously achievable only through bariatric surgery